Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

TSRA-196

Gene editing · Gene editing · developed by Tessera Therapeutics

Phase 1/2 Most advanced trial
HLSQ Developer
1 Registered trials

What is TSRA-196?

TSRA-196 is an in-vivo genome editing product formulated in lipid nanoparticles for intravenous infusion. It is being studied in patients with alpha-1 antitrypsin deficiency (AATD).

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene editing
Mechanism
Gene editing
Therapy area
Respiratory
Developer
Tessera Therapeutics, Inc. (HLSQ)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07227207 Phase 1/2 Alpha-1 Antitrypsin Deficiency (AATD) Recruiting HLSQ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alpha-1 Antitrypsin Deficiency (AATD)

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the HLSQ page.

Follow HLSQ, the company behind TSRA-196

See HLSQ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HLSQ catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.